<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00931450</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-SUT-EXE-08</org_study_id>
    <secondary_id>CDR0000640330</secondary_id>
    <secondary_id>PFIZER-ICO-SUT-EXE-08</secondary_id>
    <nct_id>NCT00931450</nct_id>
  </id_info>
  <brief_title>Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer</brief_title>
  <official_title>Pilot / Phase II Randomised, Double Blind, Placebo Controlled Multicenter Study With Biomarker Evaluation of Neoadjuvant Exemestane in Combination With Sunitinib in Post-menopausal Women With Hormone- Sensitive, Her-2 Negative Primary Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Català d'Oncologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Sunitinib malate and exemestane may stop the growth of tumor cells by blocking&#xD;
      some of the enzymes needed for cell growth. Giving sunitinib malate and exemestane before&#xD;
      surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be&#xD;
      removed.&#xD;
&#xD;
      PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of&#xD;
      sunitinib malate to see how well it works when given together with exemestane in treating&#xD;
      postmenopausal women with breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safe dose level of sunitinib malate that can be combined with exemestane&#xD;
           (pilot phase I).&#xD;
&#xD;
        -  Evaluate the clinical response of neoadjuvant therapy comprising exemestane and&#xD;
           sunitinib malate in postmenopausal women with hormone receptor-positive and HER-2&#xD;
           negative primary breast cancer (phase II).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the safety and feasibility of this regimen in these patients.&#xD;
&#xD;
        -  Evaluate the percentage of patients undergoing breast-conserving surgery after&#xD;
           completion of study therapy.&#xD;
&#xD;
        -  Determine the safety profile of this regimen in these patients.&#xD;
&#xD;
        -  Determine the rate of complete pathological response in the breast and axillary lymph&#xD;
           nodes at the time of surgery.&#xD;
&#xD;
        -  Determine the extent of treatment-related inhibition of phosphorylation of VEGFR-2,&#xD;
           PDGF, and c-KIT receptor tyrosine kinases.&#xD;
&#xD;
        -  Find a genetic profile, based on the analysis of CYP19A1 polymorphisms, able to predict&#xD;
           response to exemestane in neoadjuvant setting.&#xD;
&#xD;
        -  Conduct exploratory investigation of biomarkers expression before and during therapy in&#xD;
           order to identify molecular characteristics of responding tumors.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of sunitinib malate followed by a phase&#xD;
      II study.&#xD;
&#xD;
        -  Phase I pilot: Patients receive oral sunitinib malate and oral exemestane once daily on&#xD;
           days 1-28. Treatment repeats every 4 weeks for 6 courses in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
        -  Phase II: Patients are randomized to 1 of 2 treatment groups:&#xD;
&#xD;
             -  Group 1: Patients receive oral exemestane and oral placebo once daily on days 1-28.&#xD;
                Treatment repeats every 4 weeks for 6 courses in the absence of disease progression&#xD;
                or unacceptable toxicity.&#xD;
&#xD;
             -  Group 2: Patients receive oral exemestane once daily and oral sunitinib malate once&#xD;
                daily on days 1-28. Treatment repeats every 4 weeks for 6 courses in the absence of&#xD;
                disease progression or unacceptable toxicity.&#xD;
&#xD;
      At 7-15 days after completion of study therapy, patients undergo definitive surgery.&#xD;
&#xD;
      Blood and tissue samples are collected at baseline and periodically during study to examine&#xD;
      inhibition of phosphorylation of VEGFR-2, PDGF, and c-KIT receptor tyrosine kinases; CYP19A1&#xD;
      polymorphisms; and biomarkers analysis by cDNA microarrays, ELISA, and RT-PCR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended dose of sunitinib malate that can be combined with exemestane</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective clinical response (complete or partial response) according to WHO criteria</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and feasibility of the combination of sunitinib malate and exemestane</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of breast-conserving surgery</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of pathological complete response in the breast and axillary lymph nodes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade of inhibition of phosphorylation of VEGFR-2, PDGF, and c-KIT receptor tyrosine kinases</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic profile, based on the analysis of CYP19A1 polymorphisms, able to predict response to neoadjuvant exemestane</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular biomarkers predictive of response</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive oral exemestane and oral placebo once daily on days 1-28. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral exemestane once daily and oral sunitinib malate once daily on days 1-28. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exemestane</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed invasive breast carcinoma meeting the following criteria:&#xD;
&#xD;
               -  Estrogen receptor-positive ≥ 50% or Allred score &gt; 6&#xD;
&#xD;
               -  HER-2 negative defined as IHC &lt; 2+ and negative FISH/CISH&#xD;
&#xD;
               -  Primary tumor measuring ≥ 3 cm if there is no node involvement&#xD;
&#xD;
               -  Any T if N1 or N2 disease&#xD;
&#xD;
                    -  No inflammatory breast cancer (T4d)&#xD;
&#xD;
               -  No metastatic disease&#xD;
&#xD;
          -  Measurable disease by mammography and/or ultrasound and MRI (if available)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
               -  Prior bilateral oophorectomy&#xD;
&#xD;
               -  ≥ 60 years of age&#xD;
&#xD;
               -  &lt; 60 years of age AND have experienced amenorrhea for ≥ 12 months in the absence&#xD;
                  of chemotherapy, tamoxifen, or toremifene OR have undergone ovarian suppression&#xD;
                  and follicle-stimulating hormone and estradiol levels in the postmenopausal range&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  Albumin &gt; 2.5. g/dL&#xD;
&#xD;
          -  No known HIV infection&#xD;
&#xD;
          -  Adequate left ventricular ejection fraction (LVEF) at baseline defined as LVEF not&#xD;
             below normal range by echocardiogram or MUGA&#xD;
&#xD;
          -  No evidence of prior uncontrolled hypertension&#xD;
&#xD;
               -  Patients with controlled hypertension (systolic &lt; 150 mm Hg and/or diastolic &lt; 90&#xD;
                  mm Hg) by antihypertensive therapies allowed&#xD;
&#xD;
          -  No prior uncontrolled or symptomatic angina, myocardial infarction, congestive heart&#xD;
             failure, clinically significant arrhythmias, or prolongation of the QTc interval&#xD;
&#xD;
          -  No hemorrhagic or thrombotic events, including transient ischemic attack, pulmonary&#xD;
             embolism, or deep-vein thrombosis, within the past 12 months&#xD;
&#xD;
          -  No gross hemorrhage within the past 6 months (e.g., gastrointestinal bleeding,&#xD;
             hemoptysis, or hematuria)&#xD;
&#xD;
          -  No history or evidence of an inherited bleeding diathesis or coagulopathy at risk of&#xD;
             bleeding&#xD;
&#xD;
          -  None of the following:&#xD;
&#xD;
               -  Unable to swallow oral medications&#xD;
&#xD;
               -  Active inflammatory bowel disease&#xD;
&#xD;
               -  Partial or complete bowel obstruction&#xD;
&#xD;
               -  Chronic diarrhea&#xD;
&#xD;
          -  No history of another malignancy within the past 5 years except for cured non-melanoma&#xD;
             skin cancer or successfully treated carcinoma in situ of the cervix&#xD;
&#xD;
          -  No psychiatric disease or social situations that would limit compliance with study&#xD;
             requirements or patient unwilling or unable to comply with protocol for the duration&#xD;
             of study&#xD;
&#xD;
          -  No unstable or severe intercurrent medical condition that, in the opinion of the&#xD;
             investigator, might interfere with the achievement of study objectives&#xD;
&#xD;
          -  No known immediate or delayed hypersensitive reaction or idiosyncrasy to drugs&#xD;
             chemically related to exemestane or sunitinib malate or their excipients&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior or other concurrent chemotherapy, radiotherapy, immunotherapy, biologic&#xD;
             therapy, or hormonal therapy for primary invasive breast cancer&#xD;
&#xD;
          -  No concurrent anticoagulant therapy except for low-dose anticoagulants (i.e., low&#xD;
             molecular weight heparin or aspirin) for the prevention of deep-vein thrombosis&#xD;
&#xD;
          -  No chronic therapy with corticosteroids, except for steroids administered by&#xD;
             inhalation&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery and ≥ 7 days since prior minor surgery&#xD;
&#xD;
          -  No prior or other concurrent investigational anticancer agent&#xD;
&#xD;
          -  No concurrent participation in another clinical trial&#xD;
&#xD;
          -  No concurrent drugs with potential proarrhythmic activity&#xD;
&#xD;
          -  No concurrent known CYP3A4 inhibitors (i.e., grapefruit, verapamil, ketoconazole,&#xD;
             miconazole, itraconazole, erythromycin, clarithromycin, diltiazem, nefazodone,&#xD;
             voriconazole, telithromycin, indinavir, saquinavir, ritonavir, nelfinavir,&#xD;
             delavirdine)&#xD;
&#xD;
          -  No concurrent known CYP3A4 or CYP1A2 inducers (i.e., carbamazepine, dexamethasone,&#xD;
             felbamate, omeprazole, efavirenz, tipranavir, phenobarbital, phenytoin, primidone,&#xD;
             rifabutin, rifampicin, St. John's wort)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonia Pernas, MD</last_name>
    <affiliation>Institut Català d'Oncologia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Catala D'Oncologia</name>
      <address>
        <city>l'Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Pernas, MD</last_name>
      <phone>34-93-260-7744</phone>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>July 1, 2009</study_first_submitted>
  <study_first_submitted_qc>July 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2009</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>estrogen receptor-positive breast cancer</keyword>
  <keyword>HER2-negative breast cancer</keyword>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

